Vertebral bone marrow fat fraction changes in postmenopausal women with breast cancer receiving combined aromatase inhibitor and bisphosphonate therapy

被引：0
|
作者：
Michael Dieckmeyer
Stefan Ruschke
Alexander Rohrmeier
Jan Syväri
Ingo Einspieler
Vanadin Seifert-Klauss
Monika Schmidmayr
Stephan Metz
Jan S. Kirschke
Ernst J. Rummeny
Claus Zimmer
Dimitrios C. Karampinos
Thomas Baum
机构：
[1] Technische Universität München,Department of Diagnostic and Interventional Neuroadiology, Klinikum rechts der Isar
[2] Technische Universität München,Department of Radiology, Klinikum rechts der Isar
[3] University Medical Center Regensburg,Department of Radiology
[4] Technische Universität München,Department of Gynecology and Obstetrics, Klinikum rechts der Isar
来源：
BMC Musculoskeletal Disorders | / 20卷
关键词：
Osteoporosis; Bisphosphonates; Aromatase inhibitor; Vertebral bone marrow; Proton density fat fraction;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer
    Buzdar, Aman U.
    Coombes, R. Charles
    Goss, Paul E.
    Winer, Eric P.
    CANCER, 2008, 112 (03) : 700 - 709
  • [42] Bisphenol A exposures and hormone concentrations in a cohort of women receiving aromatase inhibitor therapy for breast cancer.
    Robien, Kimberly
    Kirstein, Mark N.
    Pawloski, Pamala A.
    Shapiro, Alice C.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [43] Screening for Osteoporosis in Postmenopausal Women With Breast Cancer Receiving Aromatase Inhibitors: Less Is More?
    Dhesy-Thind, Sukhbinder K.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (13) : 1408 - 1410
  • [44] Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole
    Brufsky, Adam
    Bundred, Nigel
    Coleman, Robert
    Lambert-Falls, Rosemary
    Mena, Raul
    Hadji, Peyman
    Jin, Lixian
    Schenk, Nora
    Ericson, Solveig
    Perez, Edith A.
    ONCOLOGIST, 2008, 13 (05): : 503 - 514
  • [45] Treatment with aromatase inhibitors for breast cancer is associated with bone loss in postmenopausal women
    不详
    Drugs & Therapy Perspectives, 2009, 25 (10) : 23 - 26
  • [46] AROMATASE INHIBITOR- INDUCED CHANGES IN THE LIPID PROFILE OF POSTMENOPAUSAL WOMEN WITH EARLY STAGE BREAST CANCER.
    Bell, L. N.
    Nguyen, A. T.
    Li, L.
    Desta, Z.
    Flockhart, D. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S79 - S79
  • [47] Neuropsychological Functioning in Breast Cancer Patients Receiving Adjuvant Aromatase Inhibitor Therapy
    Weaver, J. R.
    Stark, S. M.
    Shaverdi, K. T.
    Jeter, S.
    Zorzi, J.
    Skolasky, R. L.
    Andrejczuk, M. A.
    Sterans, V
    Gordon, B.
    CLINICAL NEUROPSYCHOLOGIST, 2011, 25 (05) : 883 - 883
  • [48] Bisphosphonate therapy requirement during adjuvant aromatase inhibitor therapy in early breast cancer patients according to UK bone health guidelines
    Moe, M.
    Almatari, M.
    Ali, P.
    Willshaw, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [49] The Interaction of Lean Body Mass With Fat Body Mass Is Associated With Vertebral Fracture Prevalence in Women With Early Breast Cancer Undergoing Aromatase Inhibitor Therapy
    Monteverdi, Sara
    Pedersini, Rebecca
    Gallo, Fabio
    Maffezzoni, Filippo
    Dalla Volta, Alberto
    Di Mauro, Pierluigi
    Turla, Antonella
    Vassalli, Lucia
    Ardine, Mara
    Formenti, Anna Maria
    Simoncini, Edda Lucia
    Giustina, Andrea
    Maroldi, Roberto
    Amoroso, Vito
    Berruti, Alfredo
    JBMR PLUS, 2021, 5 (02)
  • [50] The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women
    Mouridsen, HT
    Robert, NJ
    EUROPEAN JOURNAL OF CANCER, 2005, 41 (12) : 1678 - 1689
12345